Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11787802 Dihydrobenzimidazolones for medical treatment

Patent 11787802 was granted and assigned to C4 Therapeutics on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

C4 Therapeutics

Current Assignee

C4 Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Roger Norcross

Eric Andre Kusznir

Annick Goergler

Fabian Dey

Date of Patent

October 17, 2023

Patent Application Number

17576582

Date Filed

January 14, 2022

Patent Citations

US Patent 7208157 Proteolysis targeting chimeric pharmaceutical

US Patent 9125915 Antitumor agent

US Patent 9249161 Bromodomain inhibitors and uses thereof

Patent Citations Received

0

Patent Primary Examiner

Kristin A Vajda

CPC Code

...

Patent abstract

The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11787802 Dihydrobenzimidazolones for medical treatment

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool